Amgen Inc - Company Profile
Powered by
All the data and insights you need on Amgen Inc in one report.
- Save hours of research time and resources with
our up-to-date Amgen Inc Strategy Report
- Understand Amgen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBusiness Description
Amgen Inc (Amgen) discovers, develops, manufactures, and markets novel human medicines in six focused disease areas, namely, cancer, inflammation, cardiovascular disease, nephrology, bone health and neurological disorders.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
R&D efforts enable Amgen to develop novel human medicines for treating serious illnesses in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neurological conditions. Its pipeline includes a mix of novel molecules, potential new indications and biosimilars. As of February 2022, the company’s pipeline had 55 candidates (21 in Phase I; 11 in Phase II; and 23 in Phase III) with strong genetic support. In FY2022, the company spent US$4,434 million on R&D, which as a percentage of revenue stood at 16.8%. It has major R&D centers in the US (including Cambridge, Massachusetts, and Thousand Oaks and San Francisco, California), Canada, China, Germany, Iceland, Japan, the UK and other countries. It owns numerous US and foreign patents covering pharmaceutical products and their uses, product manufacturing processes and pharmaceutical formulations.
Business Segments
Overview
Offers human medicines in six areas: cardiovascular disease, cancer, bone health, neuroscience, nephrology and inflammation. Major products include Enbrel for active rheumatoid arthritis, moderate-to-severe plaque psoriasis and active psoriatic arthritis; Neulasta to reduce the chance of infection due to a low WBC count in people with certain types of cancer; Aranesp, for patients with anemia due to chronic kidney disease; Prolia to treat osteoporosis in women after menopause; Sensipar/Mimpara for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who are on dialysis; Xgeva to prevent serious bone problems in patients with bone metastases from solid tumors; and Epogen to treat anemia caused by CKD in patients on dialysis. Envisages product innovation, acquisitions and partnerships as critical factors for growth.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Other Revenue comprises of royalty income and corporate partner revenue.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward